Compare iShares Gold Trust (IAU) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Neurocrine Biosciences Inc — how do they compare? iShares Gold Trust trades at $78.7 (market cap $61.51B), while Neurocrine Biosciences Inc trades at $141.13 (market cap $14.36B). The key difference: iShares Gold Trust is far larger — about 4.3× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and Neurocrine Biosciences Inc for 23 Days on average.
| IAU | NBIX | |
|---|---|---|
Market Cap | $61.51B | $14.36B |
Volume | 3,206,729 | 1,237,180 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $185.50 |
52-Week Low | $74.21 | $123.10 |
Typical Hold Time | 49 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU is trading at $78.60, up 2.0% over the past 24 hours, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock faces resistance near $78-$79, with support at $76-$77. Recent news highlights sensitivity to interest rate expectations and Treasury yields, with gold's performance influencing sentiment. Financial ratios are currently unavailable for analysis.
The outlook remains cautious due to bearish technicals and macroeconomic pressures from rising yields. Investment opportunities may arise if the stock holds key support levels amid potential Fed policy shifts, but risks include further downside if rate-hike fears persist or economic data weakens gold's appeal.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
